Cargando…
Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in hematological malignancies treatment, driving an ever-expanding number of basic research and clinical trials of genetically engineering T cells to treat solid tumors. CAR T-cell therapies based on the antibodies target...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972219/ https://www.ncbi.nlm.nih.gov/pubmed/35372786 http://dx.doi.org/10.1093/abt/tbac006 |
_version_ | 1784679794504368128 |
---|---|
author | Xu, Caili Ju, Dianwen Zhang, Xuyao |
author_facet | Xu, Caili Ju, Dianwen Zhang, Xuyao |
author_sort | Xu, Caili |
collection | PubMed |
description | Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in hematological malignancies treatment, driving an ever-expanding number of basic research and clinical trials of genetically engineering T cells to treat solid tumors. CAR T-cell therapies based on the antibodies targeting Mesothelin, CEA, EGFR, EGFR, MUC1, DLL3, and emerging novel targets provide promising efficacy for lung cancer patients. However, clinical application of CAR T-cell therapy against lung cancer remains limited on account of physical and immune barriers, antigen escape and heterogeneity, on-target off-tumor toxicity, and many other reasons. Understanding the evolution of CAR structure and the generalizable requirements for manufacturing CAR T cells as well as the interplay between lung tumor immunology and CAR T cells will improve clinical translation of this therapeutic modality in lung cancer. In this review, we systematically summarize the latest advances in CAR T-cell therapy in lung cancer, focusing on the CAR structure, target antigens, challenges, and corresponding new strategies. |
format | Online Article Text |
id | pubmed-8972219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-89722192022-04-01 Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer Xu, Caili Ju, Dianwen Zhang, Xuyao Antib Ther Review Article Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in hematological malignancies treatment, driving an ever-expanding number of basic research and clinical trials of genetically engineering T cells to treat solid tumors. CAR T-cell therapies based on the antibodies targeting Mesothelin, CEA, EGFR, EGFR, MUC1, DLL3, and emerging novel targets provide promising efficacy for lung cancer patients. However, clinical application of CAR T-cell therapy against lung cancer remains limited on account of physical and immune barriers, antigen escape and heterogeneity, on-target off-tumor toxicity, and many other reasons. Understanding the evolution of CAR structure and the generalizable requirements for manufacturing CAR T cells as well as the interplay between lung tumor immunology and CAR T cells will improve clinical translation of this therapeutic modality in lung cancer. In this review, we systematically summarize the latest advances in CAR T-cell therapy in lung cancer, focusing on the CAR structure, target antigens, challenges, and corresponding new strategies. Oxford University Press 2022-02-23 /pmc/articles/PMC8972219/ /pubmed/35372786 http://dx.doi.org/10.1093/abt/tbac006 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Article Xu, Caili Ju, Dianwen Zhang, Xuyao Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer |
title | Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer |
title_full | Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer |
title_fullStr | Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer |
title_full_unstemmed | Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer |
title_short | Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer |
title_sort | chimeric antigen receptor t-cell therapy: challenges and opportunities in lung cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972219/ https://www.ncbi.nlm.nih.gov/pubmed/35372786 http://dx.doi.org/10.1093/abt/tbac006 |
work_keys_str_mv | AT xucaili chimericantigenreceptortcelltherapychallengesandopportunitiesinlungcancer AT judianwen chimericantigenreceptortcelltherapychallengesandopportunitiesinlungcancer AT zhangxuyao chimericantigenreceptortcelltherapychallengesandopportunitiesinlungcancer |